Broadcast Date: 
  • Time: 

The ever increasing pressure to accelerate drug development by reducing the time to establish strong biological rational, and implement robust discovery programs while maintaining high data quality, has resulted in the advancement of enabling technologies. In the world of ion channel focused drug discovery, this has involved the development and evolution of high-throughput electrophysiology platforms that maintain the high fidelity of the gold-standard patch clamp platform while greatly increasing throughput. This webinar will focus on the application of Nanion Syncropatch 384PE automated electrophysiology platform to enable better understanding of how human disease associated mutations alter ion channel function, and also facilitate drug candidate characterization. Specifically, high-throughput functional annotation of human ion channel variants associated with excitation disorders will be described along with use of the Syncropatch 384PE to measure subtype selective activation of Kv7 potassium channels as well as inhibition of voltage gated sodium channels like Nav1.7, Nav1.1, and Nav1.5.

Who Should Attend

  • Ion channel investigators from academia and pharma
  • Investigators interested in human excitation disorders
  • Precision medicine focused researchers

You Will Learn

  • Characterization of functional changes in voltage-dependent potassium and sodium channel properties associated with human disease causing mutations
  • Use of Syncropatch 384PE for identifying and characterizing subtype selective modulators of voltage-gated potassium and sodium channels

Produced with support from:

Sponsor Logo


Alfred George, M.D.
Chair, Department of Pharmacology,
Northwestern University Feinberg School of Medicine

Matt Fuller, Ph.D.
Senior Scientist,